Gossamer Hopes To Stand Out In Crowded Spaces
The company plans to release topline results this year in ulcerative colitis and pulmonary arterial hypertension. In UC, especially, Gossamer is aiming for an opportunity that remains untapped.
You may also be interested in...
The company will devote resources to its program to develop seralutinib in pulmonary arterial hypertension after announcing that it would discontinue GB5121 in CNS lymphoma.
Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.
Deucravacitinib is an oral drug in development for a wide range of autoimmune conditions, including psoriasis and psoriatic arthritis.